Connect Biopharma (NASDAQ:CNTB) Issues Earnings Results

Connect Biopharma (NASDAQ:CNTB) released its earnings results on Tuesday. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.05), Zacks reports. The company had revenue of $0.02 million for the quarter.

Connect Biopharma Price Performance

CNTB traded up $0.07 during trading on Thursday, hitting $2.52. 102,182 shares of the company traded hands, compared to its average volume of 198,104. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.01. The company has a market cap of $142.43 million, a PE ratio of -2.22 and a beta of -0.21. The stock’s 50-day simple moving average is $2.74 and its two-hundred day simple moving average is $2.51. Connect Biopharma has a 1 year low of $0.70 and a 1 year high of $3.82.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Connect Biopharma in a report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Connect Biopharma in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Connect Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Insider Activity at Connect Biopharma

In other news, Director James Huang acquired 1,160,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average price of $3.45 per share, for a total transaction of $4,002,000.00. Following the completion of the transaction, the director directly owned 13,160,000 shares in the company, valued at approximately $45,402,000. This trade represents a 9.67% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Connect Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in Connect Biopharma in the 4th quarter worth approximately $2,235,000. Knott David M Jr bought a new position in shares of Connect Biopharma during the 4th quarter valued at approximately $564,000. Jane Street Group LLC purchased a new position in shares of Connect Biopharma in the fourth quarter valued at $232,000. OMERS ADMINISTRATION Corp bought a new stake in Connect Biopharma in the fourth quarter worth $228,000. Finally, Marshall Wace LLP increased its position in Connect Biopharma by 121.2% in the fourth quarter. Marshall Wace LLP now owns 128,368 shares of the company’s stock worth $362,000 after purchasing an additional 70,337 shares during the last quarter. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Connect Biopharma News Summary

Here are the key news stories impacting Connect Biopharma this week:

• Positive Sentiment: HC Wainwright raised its Q4 2026 earnings estimate for Connect Biopharma, suggesting a slightly better outlook for that period. Source article
• Neutral Sentiment: Connect Biopharma said management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, which keeps the company visible to biotech investors but is not a major operational catalyst. Source article
• Neutral Sentiment: The company also announced it will present at an upcoming investor conference, which may support trading interest but does not change fundamentals on its own. Source article
• Negative Sentiment: HC Wainwright lowered its Q2, Q3, FY2026, FY2027, FY2028, FY2029, and FY2030 EPS estimates, reflecting a softer long-term earnings outlook for Connect Biopharma. Source article
• Negative Sentiment: Connect Biopharma’s latest quarterly results missed expectations, with EPS of -$0.34 versus the -$0.29 consensus and only $0.02 million in revenue, which can weigh on sentiment. Source article

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.